cancerhealth4 小时
FDA Grants Accelerated Approval of Bizengri for Lung and Pancreatic Cancer
Zenocutuzumab, a bispecific antibody, is indicated for non-small-cell lung cancer and pancreatic adenocarcinoma with NRG1 ...
Medpage Today on MSN19 小时
FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung Cancers
The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.
Merus’ zenocutuzumab-zbco granted accelerated approval by FDA
On December 4, 2024, the Food and Drug Administration granted accelerated approval to Merus (MRUS)’ zenocutuzumab-zbco for adults with the ...
Merus gets FDA approval of BIZENGRI in NRG1+ Pancreatic Adenocarcinoma, NSCLC
Merus (MRUS) announced that the FDA approved BIZENGRI(R) (zenocutuzumab-zbco), the first and only treatment indicated for ...
Cure Today21 小时
FDA Approves Bizengri for Some with NSCLC, Pancreatic Adenocarcinoma
The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.
Medscape7 小时
FDA Approves Bizengri for NSCLC and Pancreatic Cancers Harboring NRG1 Gene Fusion
The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.